| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net revenues | 4,480 | - | 3,891 | 4,332 |
| Cost of sales | 2,176 | - | 2,014 | 2,183 |
| Gross profit | 2,304 | - | 1,877 | 2,148 |
| Research and development expenses | 256 | - | 247 | 240 |
| Selling and marketing expenses | 656 | - | 622 | 626 |
| General and administrative expenses | 317 | - | 297 | 298 |
| Intangible assets impairments | 64 | - | 121 | 28 |
| Goodwill impairment | 0 | - | - | 600 |
| Other assets impairments, restructuring and other items | 62 | - | -22 | -23 |
| Legal settlements and loss contingencies | 60 | - | 86 | 450 |
| Other loss (income) | -7 | - | -5 | 21 |
| Operating income (loss) | 882 | - | 519 | -51 |
| Financial expenses, net | -237 | - | -225 | -272 |
| Income (loss) before income taxes | 646 | - | 294 | -324 |
| Income taxes (benefit) | 214 | - | 74 | 69 |
| Sharein (profits)losses ofassociatedcompanies, net | 2 | - | - | 3 |
| Net income (loss) | 434 | 283 | 220 | -390 |
| Net income (loss) attributable to redeemable and non-redeemable non-controlling interests | 1 | - | 6 | 47 |
| Net income (loss) attributable to teva | 433 | 282 | 214 | -437 |
| Earnings per share, basic | 0.38 | 0.25 | 0.19 | -0.39 |
| Earnings per share, diluted | 0.37 | 0.24 | 0.18 | -0.39 |
| Weighted average number of shares outstanding, basic | 1,147,000,000 | 1,147,000,000 | 1,138,000,000 | 1,133,000,000 |
| Weighted average number of shares outstanding, diluted | 1,164,000,000 | 1,161,000,000 | 1,159,000,000 | 1,133,000,000 |
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)